Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: A meta-analysis of longitudinal data

Lancet

Volumn 366, Issue 9500, 2005, Pages 1868-1874

  Dunn, David ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; PARAMETRIC TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; SURVIVAL; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 28044466931     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67757-4     Document Type: Article

References (30)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http://www.aidsinfo.nih.gov/guidelines/adult/AA_030204.pdf (accessed Aug 17, 2004)
2. B Gazzard BHIVA Writing Committee British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy HIV Med 2 2001 276 313
3. Guidelines for the use of antiretroviral agents in pediatric HIV infection http://www.aidsinfo.nih.gov/guidelines/pediatric/PED_012004.pdf (accessed Aug 17, 2004)
4. M Sharland, S Blanche, G Castelli PENTA guidelines for the use of antiretroviral therapy, 2004 HIV Medicine 5 suppl 2 2004 61 86
5. F Post, R Wood, G Maartens CD4 and total lymphocyte counts as predictors of HIV disease progression QJM 89 1996 505 508
6. N Kumarasamy, AP Mahajan, TP Flanigan Total lymphocyte count is a useful tool for timing of opportunistic infection prophylaxis in India and other resource-constrained countries J AIDS 31 2002 378 383
7. LA Spacek, M Griswold, TC Quinn Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of HAART in resource-limited settings AIDS 17 2003 1311 1317
8. R Bedell, KV Heath, RS Hogg Total lymphocyte count as a possible surrogate of CD4 cell count to priortize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings Antivir Ther 8 2003 379 384
9. MA Jacobson, L Liu, H Khayam-Bashi Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy AIDS 17 2003 917 919
10. Y Mekonnen, Dukers NHTM, E Sanders Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians AIDS 17 2003 815 819
11. T Schreibman, G Friedland Use of total lymphocyte count for monitoring response to antiretroviral therapy Clin Infect Dis 38 2004 257 262
12. LM Mofenson, DR Harris, J Moye Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings Lancet 362 2003 1625 1627
13. KA Fisher, J Wiener, J Farley Total lymphocyte count as an age-dependent surrogate for CD4 lymphocyte count in HIV-infected children 12 years of age and younger 11-16 July 2004 XV International AIDS Conference Bangkok Abstract TuOrB1150
14. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2003 Revision) 2004 World Health Organization 92 4 159155 2
15. HIV Paediatric Prognostic Markers Collaborative Study Group Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis Lancet 362 2003 1605 1611
16. Centers for Disease Control and Prevention 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age MMWR 43 RR-12 1994 1 10
17. Paediatric European Network for Treatment of AIDS (PENTA) Five-year follow-up of vertically HIV-infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial Arch Dis Child 84 2001 230 236
18. MS Pepe, M Moir Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12 1993 737 751
19. WT Shearer, HM Rosenblatt, RS Gelman Lymphocyte subsets in healthy children from birth through 18 years of age: the Paediatric AIDS Clinical Trials Group P1009 study J Allergy Clin Immunol 112 2003 973 980
20. European Collaborative Study Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? J AIDS 33 2003 635 641
21. M Rabkin, W El-Sadr, DA Katzenstein Antiretroviral treatment in resource-poor settings: clinical research priorities Lancet 360 2002 1503 1505
22. AN Phillips, AC Lepri, F Lampe When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies AIDS 17 2003 1863 1869
23. EJ Abrams, L Kuhn Should treatment be started early among all HIV-infected children and then stopped Lancet 362 2003 1595 1596
24. Forum for Collaborative HIV Research QA/QC of CD4 and viral load assays in the resource limited setting http://www.hivforum.org/publications/QAQC.pdf (accessed Aug 17, 2004)
25. B Houwen The differential cell count Lab Hematol 7 2001 89 100
26. ML Newell, H Coovadia, M Cortina-Borja Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis Lancet 364 2004 1236 1243
27. TE Taha, NI Kumwenda, DR Hoover Association of HIV-1-load and CD4 lymphocyte count with mortality among untreated African children over one year of age AIDS 14 2000 453 459
28. P Kiepiela, HM Coovadia, P Coward Age-related lymphocyte sub-population changes among healthy Africans from birth to adulthood Ann Trop Paediatr 9 1989 199 205
29. IM Lisse, P Aaby, H Whittle T-lymphocyte subsets in West African children: impact of age, sex, and season J Pediatr 130 1997 77 85
30. Sinyinza F, Mulenga V, Lishimpi K, et al. Prognostic markers of survival in HIV-infected children in the CHAP Trial, Zambia. Abstract 154. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004.